Trial Profile

A multi-country, multicenter, randomized, open-label, parallel group study to assess the efficacy and safety of Docecal compared with Taxotere

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 20 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 May 2020 Primary endpoint (Overall response rate; partial and complete response) has not been met, according to results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
31 May 2020 Results assessing PK, safety and early activity from two clinical studies: EudraCT2012-005161-12 and EudraCT2013-004889-33 presented at the 56th Annual Meeting of the American Society of Clinical Oncology
12 Sep 2018 According to an Oasmia Pharmaceutical media release, two studies (CTP 293315 and CTP 293313) will form the basis of discussion with other authorities such as EMA for Europe and the FDA for the US.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com